Cargando…

Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases

A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakimura, Shotaro, Nagayama, Satoshi, Fukunaga, Mitsuko, Hu, Qingjiang, Kitagawa, Akihiro, Kobayashi, Yuta, Hasegawa, Takanori, Noda, Miwa, Kouyama, Yuta, Shimizu, Dai, Saito, Tomoko, Niida, Atsushi, Tsuruda, Yusuke, Otsu, Hajime, Matsumoto, Yoshihiro, Uchida, Hiroki, Masuda, Takaaki, Sugimachi, Keishi, Sasaki, Shin, Yamada, Kazutaka, Takahashi, Kazuki, Innan, Hideki, Suzuki, Yutaka, Nakamura, Hiromi, Totoki, Yasushi, Mizuno, Shinichi, Ohshima, Masanobu, Shibata, Tatsuhiro, Mimori, Koshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864431/
https://www.ncbi.nlm.nih.gov/pubmed/33476333
http://dx.doi.org/10.1371/journal.pgen.1009113
_version_ 1783647661761495040
author Sakimura, Shotaro
Nagayama, Satoshi
Fukunaga, Mitsuko
Hu, Qingjiang
Kitagawa, Akihiro
Kobayashi, Yuta
Hasegawa, Takanori
Noda, Miwa
Kouyama, Yuta
Shimizu, Dai
Saito, Tomoko
Niida, Atsushi
Tsuruda, Yusuke
Otsu, Hajime
Matsumoto, Yoshihiro
Uchida, Hiroki
Masuda, Takaaki
Sugimachi, Keishi
Sasaki, Shin
Yamada, Kazutaka
Takahashi, Kazuki
Innan, Hideki
Suzuki, Yutaka
Nakamura, Hiromi
Totoki, Yasushi
Mizuno, Shinichi
Ohshima, Masanobu
Shibata, Tatsuhiro
Mimori, Koshi
author_facet Sakimura, Shotaro
Nagayama, Satoshi
Fukunaga, Mitsuko
Hu, Qingjiang
Kitagawa, Akihiro
Kobayashi, Yuta
Hasegawa, Takanori
Noda, Miwa
Kouyama, Yuta
Shimizu, Dai
Saito, Tomoko
Niida, Atsushi
Tsuruda, Yusuke
Otsu, Hajime
Matsumoto, Yoshihiro
Uchida, Hiroki
Masuda, Takaaki
Sugimachi, Keishi
Sasaki, Shin
Yamada, Kazutaka
Takahashi, Kazuki
Innan, Hideki
Suzuki, Yutaka
Nakamura, Hiromi
Totoki, Yasushi
Mizuno, Shinichi
Ohshima, Masanobu
Shibata, Tatsuhiro
Mimori, Koshi
author_sort Sakimura, Shotaro
collection PubMed
description A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that foster postoperative recurrence of CRC. CNA and neoantigens (NAG) were compared between early primary tumors with recurrence (CRCR) and early primary tumors without recurrence (precancerous and early; PCRC). We compared CNA, single nucleotide variance (SNV), RNA sequences, and T-cell receptor (TCR) repertoire between 9 primary and 10 metastatic sites from 10 CRCR cases. We found that NAG in primary sites were fewer in CRCR than in PCRC, while the arm level CNA were significantly higher in primary sites in CRCR than in PCRC. Further, a comparison of genomic aberrations of primary and metastatic conditions revealed no significant differences in CNA. The driver mutations in recurrence were the trunk of the evolutionary phylogenic tree from primary sites to recurrence sites. Notably, PD-1 and TIM3, T cell exhaustion-related molecules of the tumor immune response, were abundantly expressed in metastatic sites compared to primary sites along with the increased number of CD8 expressing cells. The postoperative recurrence-free survival period was only significantly associated with the NAG levels and TCR repertoire diversity in metastatic sites. Therefore, CNA with diminished NAG and diverse TCR repertoire in pre-metastatic sites may determine postoperative recurrence of CRC.
format Online
Article
Text
id pubmed-7864431
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-78644312021-02-12 Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases Sakimura, Shotaro Nagayama, Satoshi Fukunaga, Mitsuko Hu, Qingjiang Kitagawa, Akihiro Kobayashi, Yuta Hasegawa, Takanori Noda, Miwa Kouyama, Yuta Shimizu, Dai Saito, Tomoko Niida, Atsushi Tsuruda, Yusuke Otsu, Hajime Matsumoto, Yoshihiro Uchida, Hiroki Masuda, Takaaki Sugimachi, Keishi Sasaki, Shin Yamada, Kazutaka Takahashi, Kazuki Innan, Hideki Suzuki, Yutaka Nakamura, Hiromi Totoki, Yasushi Mizuno, Shinichi Ohshima, Masanobu Shibata, Tatsuhiro Mimori, Koshi PLoS Genet Research Article A Darwinian evolutionary shift occurs early in the neutral evolution of advanced colorectal carcinoma (CRC), and copy number aberrations (CNA) are essential in the transition from adenoma to carcinoma. In light of this primary evolution, we investigated the evolutionary principles of the genome that foster postoperative recurrence of CRC. CNA and neoantigens (NAG) were compared between early primary tumors with recurrence (CRCR) and early primary tumors without recurrence (precancerous and early; PCRC). We compared CNA, single nucleotide variance (SNV), RNA sequences, and T-cell receptor (TCR) repertoire between 9 primary and 10 metastatic sites from 10 CRCR cases. We found that NAG in primary sites were fewer in CRCR than in PCRC, while the arm level CNA were significantly higher in primary sites in CRCR than in PCRC. Further, a comparison of genomic aberrations of primary and metastatic conditions revealed no significant differences in CNA. The driver mutations in recurrence were the trunk of the evolutionary phylogenic tree from primary sites to recurrence sites. Notably, PD-1 and TIM3, T cell exhaustion-related molecules of the tumor immune response, were abundantly expressed in metastatic sites compared to primary sites along with the increased number of CD8 expressing cells. The postoperative recurrence-free survival period was only significantly associated with the NAG levels and TCR repertoire diversity in metastatic sites. Therefore, CNA with diminished NAG and diverse TCR repertoire in pre-metastatic sites may determine postoperative recurrence of CRC. Public Library of Science 2021-01-21 /pmc/articles/PMC7864431/ /pubmed/33476333 http://dx.doi.org/10.1371/journal.pgen.1009113 Text en © 2021 Sakimura et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Sakimura, Shotaro
Nagayama, Satoshi
Fukunaga, Mitsuko
Hu, Qingjiang
Kitagawa, Akihiro
Kobayashi, Yuta
Hasegawa, Takanori
Noda, Miwa
Kouyama, Yuta
Shimizu, Dai
Saito, Tomoko
Niida, Atsushi
Tsuruda, Yusuke
Otsu, Hajime
Matsumoto, Yoshihiro
Uchida, Hiroki
Masuda, Takaaki
Sugimachi, Keishi
Sasaki, Shin
Yamada, Kazutaka
Takahashi, Kazuki
Innan, Hideki
Suzuki, Yutaka
Nakamura, Hiromi
Totoki, Yasushi
Mizuno, Shinichi
Ohshima, Masanobu
Shibata, Tatsuhiro
Mimori, Koshi
Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
title Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
title_full Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
title_fullStr Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
title_full_unstemmed Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
title_short Impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in CRC cases
title_sort impaired tumor immune response in metastatic tumors is a selective pressure for neutral evolution in crc cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864431/
https://www.ncbi.nlm.nih.gov/pubmed/33476333
http://dx.doi.org/10.1371/journal.pgen.1009113
work_keys_str_mv AT sakimurashotaro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT nagayamasatoshi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT fukunagamitsuko impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT huqingjiang impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT kitagawaakihiro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT kobayashiyuta impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT hasegawatakanori impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT nodamiwa impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT kouyamayuta impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT shimizudai impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT saitotomoko impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT niidaatsushi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT tsurudayusuke impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT otsuhajime impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT matsumotoyoshihiro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT uchidahiroki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT masudatakaaki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT sugimachikeishi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT sasakishin impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT yamadakazutaka impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT takahashikazuki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT innanhideki impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT suzukiyutaka impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT nakamurahiromi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT totokiyasushi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT mizunoshinichi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT ohshimamasanobu impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT shibatatatsuhiro impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases
AT mimorikoshi impairedtumorimmuneresponseinmetastatictumorsisaselectivepressureforneutralevolutionincrccases